{
    "xml": "<topic id=\"PHP5210\" outputclass=\"drug\" rev=\"1.11\" type=\"drug\" namespace=\"/drugs/folinic-acid\" basename=\"folinic-acid\" title=\"FOLINIC ACID\">\n<title>FOLINIC ACID</title>\n<body>\r\n<p outputclass=\"interactionsLinks\"> List of individual interactants: <xref format=\"dita\" href=\"#bnf_int_861\" namespace=\"/interactions/list-of-drug-interactions/folates/folinic-acid\">Folinic Acid</xref>\n</p>\n<data name=\"vtmid\">1528001</data>\n<data name=\"classifications\">\n<data name=\"classification\">\n<data name=\"drugClassification\">\n<xref format=\"dita\" scope=\"local\" type=\"drugClassification\" href=\"#_251481106\" title=\"Folates\">Folates</xref>\n</data>\n</data>\n</data>\n<data name=\"primaryDomainOfEffect\">\n<data name=\"domainOfEffect\">  </data>\n</data>\r\n</body>\n<topic id=\"PHP72907\" outputclass=\"indicationsAndDose\" rev=\"1.17\" parent=\"/drugs/folinic-acid\">\n<title>Indications and dose</title>\n<body>\n<section outputclass=\"indicationAndDoseGroup\">\n<sectiondiv outputclass=\"therapeuticIndications\">\n<p outputclass=\"therapeuticIndication\">Prevention of methotrexate-induced adverse effects</p>\n</sectiondiv>\n<p outputclass=\"routesOfAdministration\">By intramuscular injection or by intravenous injection or by intravenous infusion</p>\n<ul outputclass=\"patientGroups\">\n<li outputclass=\"patientGroup adult\">\n<p>Adult</p>\n<p>15&#8239;mg every 6&#8239;hours for 24 hours, to be started usually 12&#8211;24 hours after start of methotrexate infusion, dose may be continued by mouth, consult local treatment protocol for further information.</p>\n</li>\n</ul>\n</section>\n<section outputclass=\"indicationAndDoseGroup\">\n<sectiondiv outputclass=\"therapeuticIndications\">\n<p outputclass=\"therapeuticIndication\">Suspected methotrexate overdosage</p>\n</sectiondiv>\n<p outputclass=\"routesOfAdministration\">By intravenous injection or by intravenous infusion</p>\n<ul outputclass=\"patientGroups\">\n<li outputclass=\"patientGroup adult\">\n<p>Adult</p>\n<p>Initial dose equal to or exceeding dose of methotrexate, to be given at a maximum rate of 160&#8239;mg/minute, consult poisons information centres for advice on continuing management.</p>\n</li>\n</ul>\n</section>\n<section outputclass=\"indicationAndDoseGroup\">\n<sectiondiv outputclass=\"therapeuticIndications\">\n<p outputclass=\"therapeuticIndication\">Adjunct to fluorouracil in colorectal cancer</p>\n</sectiondiv>\n<p outputclass=\"routesOfAdministration\">By slow intravenous injection</p>\n<ul outputclass=\"patientGroups\">\n<li outputclass=\"patientGroup adult\">\n<p>Adult</p>\n<p>(consult product literature).</p>\n</li>\n</ul>\n</section>\n</body>\n</topic>\n<topic id=\"PHP72936\" outputclass=\"contraindications\" rev=\"1.13\" parent=\"/drugs/folinic-acid\">\n<title>Contra-indications</title>\n<body>\n<section outputclass=\"contraindications\">\n<p>\n<ph outputclass=\"contraindication\">Intrathecal injection</ph>\n</p>\n</section>\n</body>\n</topic>\n<topic id=\"PHP72949\" outputclass=\"cautions\" rev=\"1.8\" parent=\"/drugs/folinic-acid\">\n<title>Cautions</title>\n<body>\n<section outputclass=\"cautions\">\n<p>\n<ph outputclass=\"caution\">\n<b>not</b> indicated for pernicious anaemia or other megaloblastic anaemias caused by vitamin B<sub>12</sub> deficiency</ph>; <ph outputclass=\"caution\">avoid simultaneous administration of methotrexate</ph>\n</p>\n</section>\n</body>\n</topic>\n<topic id=\"PHP72904\" outputclass=\"interactions\" rev=\"1.7\" parent=\"/drugs/folinic-acid\">\n<title>Interactions</title>\n<body>\n<section outputclass=\"general\">\n<sectiondiv>\n<p>Appendix 1 (folates).</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP72880\" outputclass=\"sideEffects\" rev=\"1.12\" parent=\"/drugs/folinic-acid\">\n<title>Side-effects</title>\n<body>\n<section outputclass=\"generalSideEffects\">\n<sectiondiv outputclass=\"frequencies\">\n<sectiondiv outputclass=\"rare\">\n<p outputclass=\"title\">Rare</p>\n<p outputclass=\"sideEffects\">\n<ph outputclass=\"sideEffect\">Agitation (after high doses)</ph>; <ph outputclass=\"sideEffect\">depression (after high doses)</ph>; <ph outputclass=\"sideEffect\">insomnia (after high doses)</ph>; <ph outputclass=\"sideEffect\">pyrexia (after parenteral use)</ph>\n</p>\n</sectiondiv>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP72898\" outputclass=\"pregnancy\" parent=\"/drugs/folinic-acid\">\n<title>Pregnancy</title>\n<body>\n<section outputclass=\"generalInformation\">\n<sectiondiv>\n<p>Not known to be harmful; benefit outweighs risk.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP72956\" outputclass=\"breastFeeding\" parent=\"/drugs/folinic-acid\">\n<title>Breast feeding</title>\n<body>\n<section outputclass=\"generalInformation\">\n<sectiondiv>\n<p>Presence in milk unknown but benefit outweighs risk.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP72853\" outputclass=\"nationalFunding\" rev=\"1.20\" parent=\"/drugs/folinic-acid\">\n<title>National funding/access decisions</title>\n<body>\r\n<section>\r\n<sectiondiv outputclass=\"niceTechnologyAppraisals\">\r\n<p outputclass=\"title\">NICE technology appraisals (TAs)</p>\r\n<sectiondiv outputclass=\"niceTechnologyAppraisal\">\r\n<p outputclass=\"fundingIdentifier\">NICE TA212</p>\r\n<sectiondiv>\r\n<p outputclass=\"title\"> Bevacizumab in combination with oxaliplatin and either fluorouracil plus folinic acid or capecitabine for the treatment of metastatic colorectal cancer (December 2010)</p>\r\n<p>Bevacizumab in combination with oxaliplatin and either fluorouracil plus folinic acid or capecitabine is not recommended for the treatment of metastatic colorectal cancer.</p>\n</sectiondiv>\n<xref format=\"html\" href=\"http://www.nice.org.uk/TA212\">www.nice.org.uk/TA212</xref>\n</sectiondiv>\n</sectiondiv>\r\n </section>\r\n\r\n</body>\n</topic>\n<topic id=\"PHP5210-medicinalForms\" outputclass=\"medicinalForms\" parent=\"/drugs/folinic-acid\">\n<title>Medicinal forms</title>\n<body>\n<section outputclass=\"licensingVariationStatement\">\n<p>There can be variation in the licensing of different medicines containing the same drug.</p>\n</section>\n<p>Forms available from special-order manufacturers include: oral solution, oral suspension</p>\n</body>\n</topic>\n<parents>\n<xref format=\"dita\" scope=\"local\" type=\"drugs\" href=\"#drugs\" title=\"Drugs\" namespace=\"/drugs\">Drugs</xref>\n</parents>\n<children>\n<xref format=\"dita\" scope=\"local\" type=\"medicinalForm\" href=\"#PHP76541\" title=\"Tablet\" namespace=\"/drugs/folinic-acid/tablet\">Tablet</xref>\n<xref format=\"dita\" scope=\"local\" type=\"medicinalForm\" href=\"#PHP76575\" title=\"Solution for injection\" namespace=\"/drugs/folinic-acid/solution-for-injection\">Solution for injection</xref>\n</children>\n<backlinks>\n<xref format=\"dita\" scope=\"local\" type=\"drugClassifications\" href=\"#PHP106980\" namespace=\"/drug-classifications\" title=\"Drug classifications\" count=\"1\" rel=\"backlink\">Drug classifications</xref>\n<xref format=\"dita\" scope=\"local\" type=\"treatmentSummary\" href=\"#PHP78195\" namespace=\"/treatment-summaries/vitamins\" title=\"Vitamins\" count=\"1\" rel=\"backlink\">Vitamins</xref>\n<xref format=\"dita\" scope=\"local\" type=\"treatmentSummary\" href=\"#PHP78537\" namespace=\"/treatment-summaries/cytotoxic-drugs\" title=\"Cytotoxic drugs\" count=\"6\" rel=\"backlink\">Cytotoxic drugs</xref>\n<xref format=\"dita\" scope=\"local\" type=\"treatmentSummary\" href=\"#PHP78590\" namespace=\"/treatment-summaries/anaemias\" title=\"Anaemias\" count=\"1\" rel=\"backlink\">Anaemias</xref>\n</backlinks>\n<links>\n<xref format=\"dita\" scope=\"local\" type=\"interaction\" href=\"#bnf_int_861\" namespace=\"/interactions/list-of-drug-interactions/folates/folinic-acid\" title=\"Folinic Acid\" count=\"1\" rel=\"link\">Folinic Acid</xref>\n<xref format=\"dita\" scope=\"local\" type=\"#drugs\" href=\"#drugs\" namespace=\"/drugs\" title=\"Drugs\" count=\"1\" rel=\"link\">Drugs</xref>\n<xref format=\"dita\" scope=\"local\" type=\"medicinalForm\" href=\"#PHP76541\" namespace=\"/drugs/folinic-acid/tablet\" title=\"Tablet\" count=\"1\" rel=\"link\">Tablet</xref>\n<xref format=\"dita\" scope=\"local\" type=\"medicinalForm\" href=\"#PHP76575\" namespace=\"/drugs/folinic-acid/solution-for-injection\" title=\"Solution for injection\" count=\"1\" rel=\"link\">Solution for injection</xref>\n</links>\n</topic>",
    "id": "PHP5210",
    "outputclass": "drug",
    "rev": "1.11",
    "type": "drug",
    "namespace": "/drugs/folinic-acid",
    "basename": "folinic-acid",
    "title": "FOLINIC ACID",
    "interactants": [
        {
            "id": "bnf_int_861",
            "label": "Folinic Acid"
        }
    ],
    "vtmid": "1528001",
    "drugClassification": [
        "Folates"
    ],
    "primaryDomainOfEffect": {
        "": {
            "domain": "",
            "therapeuticUses": {}
        }
    },
    "indicationsAndDoses": {
        "indicationAndDoseGroups": [
            {
                "indications": [
                    {
                        "textContent": "Prevention of methotrexate-induced adverse effects",
                        "html": "Prevention of methotrexate-induced adverse effects"
                    }
                ],
                "specificity": {
                    "routes": [
                        "intramuscular injection or intravenous injection or intravenous infusion"
                    ],
                    "textContent": "By intramuscular injection or by intravenous injection or by intravenous infusion",
                    "html": "By intramuscular injection or by intravenous injection or by intravenous infusion"
                },
                "adult": [
                    {
                        "textContent": "15 mg every 6 hours for 24 hours, to be started usually 12&#8211;24 hours after start of methotrexate infusion, dose may be continued by mouth, consult local treatment protocol for further information.",
                        "html": "<p>15&#8239;mg every 6&#8239;hours for 24 hours, to be started usually 12&#8211;24 hours after start of methotrexate infusion, dose may be continued by mouth, consult local treatment protocol for further information.</p>"
                    }
                ]
            },
            {
                "indications": [
                    {
                        "textContent": "Suspected methotrexate overdosage",
                        "html": "Suspected methotrexate overdosage"
                    }
                ],
                "specificity": {
                    "routes": [
                        "intravenous injection or intravenous infusion"
                    ],
                    "textContent": "By intravenous injection or by intravenous infusion",
                    "html": "By intravenous injection or by intravenous infusion"
                },
                "adult": [
                    {
                        "textContent": "Initial dose equal to or exceeding dose of methotrexate, to be given at a maximum rate of 160 mg/minute, consult poisons information centres for advice on continuing management.",
                        "html": "<p>Initial dose equal to or exceeding dose of methotrexate, to be given at a maximum rate of 160&#8239;mg/minute, consult poisons information centres for advice on continuing management.</p>"
                    }
                ]
            },
            {
                "indications": [
                    {
                        "textContent": "Adjunct to fluorouracil in colorectal cancer",
                        "html": "Adjunct to fluorouracil in colorectal cancer"
                    }
                ],
                "specificity": {
                    "routes": [
                        "slow intravenous injection"
                    ],
                    "textContent": "By slow intravenous injection",
                    "html": "By slow intravenous injection"
                },
                "adult": [
                    {
                        "textContent": "(consult product literature).",
                        "html": "<p>(consult product literature).</p>"
                    }
                ]
            }
        ]
    },
    "contraindications": {
        "contraindications": [
            {
                "type": "contraindications",
                "textContent": "Intrathecal injection",
                "html": "Intrathecal injection"
            }
        ]
    },
    "cautions": {
        "cautions": [
            {
                "type": "cautions",
                "textContent": "not indicated for pernicious anaemia or other megaloblastic anaemias caused by vitamin B12 deficiency",
                "html": "<b>not</b> indicated for pernicious anaemia or other megaloblastic anaemias caused by vitamin B<sub>12</sub> deficiency"
            },
            {
                "type": "cautions",
                "textContent": "avoid simultaneous administration of methotrexate",
                "html": "avoid simultaneous administration of methotrexate"
            }
        ]
    },
    "interactions": {
        "general": [
            {
                "type": "general",
                "textContent": "Appendix 1 (folates).",
                "html": "<p>Appendix 1 (folates).</p>"
            }
        ]
    },
    "sideEffects": {
        "general": {
            "frequencies": {
                "rare": [
                    {
                        "type": "rare",
                        "textContent": "Agitation (after high doses)",
                        "html": "Agitation (after high doses)",
                        "frequency": "rare",
                        "specificity": {
                            "textContent": "Rare",
                            "html": "Rare"
                        }
                    },
                    {
                        "type": "rare",
                        "textContent": "depression (after high doses)",
                        "html": "depression (after high doses)",
                        "frequency": "rare",
                        "specificity": {
                            "textContent": "Rare",
                            "html": "Rare"
                        }
                    },
                    {
                        "type": "rare",
                        "textContent": "insomnia (after high doses)",
                        "html": "insomnia (after high doses)",
                        "frequency": "rare",
                        "specificity": {
                            "textContent": "Rare",
                            "html": "Rare"
                        }
                    },
                    {
                        "type": "rare",
                        "textContent": "pyrexia (after parenteral use)",
                        "html": "pyrexia (after parenteral use)",
                        "frequency": "rare",
                        "specificity": {
                            "textContent": "Rare",
                            "html": "Rare"
                        }
                    }
                ]
            }
        }
    },
    "pregnancy": {
        "generalInformation": [
            {
                "type": "generalInformation",
                "textContent": "Not known to be harmful; benefit outweighs risk.",
                "html": "<p>Not known to be harmful; benefit outweighs risk.</p>"
            }
        ]
    },
    "breastFeeding": {
        "generalInformation": [
            {
                "type": "generalInformation",
                "textContent": "Presence in milk unknown but benefit outweighs risk.",
                "html": "<p>Presence in milk unknown but benefit outweighs risk.</p>"
            }
        ]
    },
    "nationalFunding": {
        "niceTechnologyAppraisals": [
            {
                "type": "niceTechnologyAppraisals",
                "references": [
                    {
                        "id": "http://www.nice.org.uk/TA212",
                        "label": "www.nice.org.uk/TA212"
                    }
                ],
                "fundingIdentifier": "NICE TA212",
                "textContent": "Bevacizumab in combination with oxaliplatin and either fluorouracil plus folinic acid or capecitabine for the treatment of metastatic colorectal cancer (December 2010) Bevacizumab in combination with oxaliplatin and either fluorouracil plus folinic acid or capecitabine is not recommended for the treatment of metastatic colorectal cancer.\n\nwww.nice.org.uk/TA212",
                "html": "<p outputclass=\"title\"> Bevacizumab in combination with oxaliplatin and either fluorouracil plus folinic acid or capecitabine for the treatment of metastatic colorectal cancer (December 2010)</p> <p>Bevacizumab in combination with oxaliplatin and either fluorouracil plus folinic acid or capecitabine is not recommended for the treatment of metastatic colorectal cancer.</p><xref format=\"html\" href=\"http://www.nice.org.uk/TA212\">www.nice.org.uk/TA212</xref>"
            }
        ]
    },
    "medicinalForms": {
        "licensingVariationStatement": [
            {
                "type": "licensingVariationStatement",
                "textContent": "There can be variation in the licensing of different medicines containing the same drug.",
                "html": "<p>There can be variation in the licensing of different medicines containing the same drug.</p>"
            }
        ],
        "availableForms": {
            "before": "Forms available from special-order manufacturers include",
            "forms": [
                "oral solution",
                "oral suspension"
            ]
        }
    },
    "children": {
        "medicinalForm": [
            {
                "id": "PHP76541",
                "label": "Tablet",
                "type": "medicinalForm"
            },
            {
                "id": "PHP76575",
                "label": "Solution for injection",
                "type": "medicinalForm"
            }
        ]
    },
    "backlinks": {
        "drugClassifications": [
            {
                "id": "PHP106980",
                "label": "Drug classifications",
                "type": "drugClassifications"
            }
        ],
        "treatmentSummary": [
            {
                "id": "PHP78195",
                "label": "Vitamins",
                "type": "treatmentSummary"
            },
            {
                "id": "PHP78537",
                "label": "Cytotoxic drugs",
                "type": "treatmentSummary"
            },
            {
                "id": "PHP78590",
                "label": "Anaemias",
                "type": "treatmentSummary"
            }
        ]
    },
    "links": {
        "interaction": [
            {
                "id": "bnf_int_861",
                "label": "Folinic Acid",
                "type": "interaction"
            }
        ],
        "#drugs": [
            {
                "id": "drugs",
                "label": "Drugs",
                "type": "#drugs"
            }
        ],
        "medicinalForm": [
            {
                "id": "PHP76541",
                "label": "Tablet",
                "type": "medicinalForm"
            },
            {
                "id": "PHP76575",
                "label": "Solution for injection",
                "type": "medicinalForm"
            }
        ]
    }
}